Adding an IVCF to fondaparinux did not show a benefit in terms of safety (major bleeding complications were only <5% and similar in both arms), efficacy (complete VTE resolution occurred in 51% of patients within 8 weeks), or survival (a negative trend in IVCF arm was due to a higher rate of advanced colon and pancreatic cancer with dismal prognosis assigned to IVCF arm).
← all excerpts
Inferior Vena Cava Filter in Cancer-Associated Thrombosis: A <i>Vade Mecum</i> for the Treating Physicians: A Narrative Review.
1
—
—